Interim results from RAINIER reveal that an 80 mg dose of povetacicept every four weeks delivered a 52% reduction in protein ...

Around half a million women in England will soon be able to access a non-hormonal treatment for hot flushes associated with menopause, after Astellas' Veoza was cleared for NHS use.

The Evolution Summit, taking place May 7-8, 2026 at The Ritz-Carlton, Fort Lauderdale, Florida. Designed as an ...

Genmab's recently approved therapy for cervical cancer that has come back or spread, Tivdak, has been turned down for NHS use in initial guidance from reimbursement authority NICE. Tivdak (tisotumab ...

Novo Nordisk has been sent a warning letter from the FDA for a series of violations of postmarketing adverse drug experience (PADE) regulations, including failure to report side effects among patients ...

Veeva Systems has built its presence in brand engagement with the acquisition of Ostro, a tech startup that helps pharma companies connect with doctors and patients using AI-powered conversational ...

They are due to leave by the end of this year to set up an as-yet unnamed "independent biotechnology company to research and ...

Steve Sanghera is the CEO and co-founder of Inventus. With over 20 years of experience in technology and telecommunications, ...

Ipsen said it will now pull Tazverik from the market in all countries where it has rights to the first-in-class, chemotherapy ...

In a move that will delight Novo Nordisk and Eli Lilly, the FDA has sent warning letters to 30 telehealth companies, accusing them of illegally marketing compounded GLP-1 agonist formulations. The ...

In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...

Genetic diseases are notoriously challenging to treat, especially when each condition requires a tailored approach. With over 10,000 known genetic disorders, developing individual therapies for each ...